A phase 1/2, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of AGEN2034 in subjects with metastatic or locally advanced solid tumors, with expansion to second line cervical cancer [C-700-001].

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

Effective start/end date10/09/1931/12/24


  • Medical Oncology
  • Solid Tumors
  • Cervical Cancer
  • Clinical trial